Home > Science > American group grants $600,000 for Israeli cancer research

American group grants $600,000 for Israeli cancer research

September 17, 2010 Leave a comment Go to comments

BEER-SHEVA, Israel (Press Release) – Ben-Gurion University of the Negev (BGU) Professor Varda Shoshan-Barmatz has been awarded a three-year, $600,000 grant from the U.S. Leukemia & Lymphoma Society to develop target-specific, anti-cancer drugs.

Professor Shoshan-Barmatz, the Hyman Kreitman Chair in Bioenergetics at BGU, has developed a peptide that targets and kills cancer cells while sparing normal cells. The drugs she will be developing target B-CLL (B-cell chronic lymphocytic leukemia), one of the most common and incurable hematological malignancies.

“Conventional chemotherapy is limited by its lack of specificity, multi-drug resistance of tumor cells, and toxicity to normal cells,” says  Shoshan-Barmatz. “The benefits to be gained by this new drug are enormous. These therapeutic peptides have a great potential as ant-cancer agents due to their target specificity and potential for reduced side-effects.” 

Prof. Varda Shoshan-Barmatz is also the Director of the BGU National Institute for Biotechnology in the Negev. Only 10 per cent of The Leukemia & Lymphona Society grants have been awarded outside the U.S., and about one-third of the non-U.S. grants are awarded to Canada.

*
Preceding provided by American Associates of Ben Gurion University of the Negev

Advertisements
  1. No comments yet.
  1. No trackbacks yet.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: